vs

Side-by-side financial comparison of Shoals Technologies Group, Inc. (SHLS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.

Shoals Technologies Group, Inc. is the larger business by last-quarter revenue ($148.3M vs $103.7M, roughly 1.4× Twist Bioscience Corp). Shoals Technologies Group, Inc. runs the higher net margin — 5.5% vs -29.4%, a 34.9% gap on every dollar of revenue. On growth, Shoals Technologies Group, Inc. posted the faster year-over-year revenue change (38.6% vs 16.9%). Shoals Technologies Group, Inc. produced more free cash flow last quarter ($-11.3M vs $-34.8M).

Shoals Technologies Group is a leading provider of electrical balance of systems solutions for renewable energy and e-mobility. It supplies connectivity components for solar projects, energy storage systems and EV charging infrastructure, serving clients across North America, Europe and Asia-Pacific.

Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.

SHLS vs TWST — Head-to-Head

Bigger by revenue
SHLS
SHLS
1.4× larger
SHLS
$148.3M
$103.7M
TWST
Growing faster (revenue YoY)
SHLS
SHLS
+21.7% gap
SHLS
38.6%
16.9%
TWST
Higher net margin
SHLS
SHLS
34.9% more per $
SHLS
5.5%
-29.4%
TWST
More free cash flow
SHLS
SHLS
$23.5M more FCF
SHLS
$-11.3M
$-34.8M
TWST

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
SHLS
SHLS
TWST
TWST
Revenue
$148.3M
$103.7M
Net Profit
$8.1M
$-30.5M
Gross Margin
31.6%
52.0%
Operating Margin
11.7%
-31.7%
Net Margin
5.5%
-29.4%
Revenue YoY
38.6%
16.9%
Net Profit YoY
3.9%
3.4%
EPS (diluted)
$0.05
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SHLS
SHLS
TWST
TWST
Q4 25
$148.3M
$103.7M
Q3 25
$135.8M
Q2 25
$110.8M
Q1 25
$80.4M
Q4 24
$107.0M
Q3 24
$102.2M
Q2 24
$99.2M
Q1 24
$90.8M
Net Profit
SHLS
SHLS
TWST
TWST
Q4 25
$8.1M
$-30.5M
Q3 25
$11.9M
Q2 25
$13.9M
Q1 25
$-282.0K
Q4 24
$7.8M
Q3 24
$-267.0K
Q2 24
$11.8M
Q1 24
$4.8M
Gross Margin
SHLS
SHLS
TWST
TWST
Q4 25
31.6%
52.0%
Q3 25
37.0%
Q2 25
37.2%
Q1 25
35.0%
Q4 24
37.6%
Q3 24
24.8%
Q2 24
40.3%
Q1 24
40.2%
Operating Margin
SHLS
SHLS
TWST
TWST
Q4 25
11.7%
-31.7%
Q3 25
13.7%
Q2 25
14.4%
Q1 25
5.4%
Q4 24
15.4%
Q3 24
4.4%
Q2 24
18.7%
Q1 24
12.8%
Net Margin
SHLS
SHLS
TWST
TWST
Q4 25
5.5%
-29.4%
Q3 25
8.7%
Q2 25
12.5%
Q1 25
-0.4%
Q4 24
7.3%
Q3 24
-0.3%
Q2 24
11.9%
Q1 24
5.3%
EPS (diluted)
SHLS
SHLS
TWST
TWST
Q4 25
$0.05
$-0.50
Q3 25
$0.07
Q2 25
$0.08
Q1 25
$0.00
Q4 24
$0.04
Q3 24
$0.00
Q2 24
$0.07
Q1 24
$0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SHLS
SHLS
TWST
TWST
Cash + ST InvestmentsLiquidity on hand
$7.3M
$197.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$600.0M
$456.1M
Total Assets
$904.1M
$638.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SHLS
SHLS
TWST
TWST
Q4 25
$7.3M
$197.9M
Q3 25
$8.6M
Q2 25
$4.7M
Q1 25
$35.6M
Q4 24
$23.5M
Q3 24
$11.1M
Q2 24
$3.2M
Q1 24
$15.2M
Total Debt
SHLS
SHLS
TWST
TWST
Q4 25
Q3 25
Q2 25
Q1 25
$141.8M
Q4 24
$141.8M
Q3 24
$141.8M
Q2 24
$146.8M
Q1 24
$168.8M
Stockholders' Equity
SHLS
SHLS
TWST
TWST
Q4 25
$600.0M
$456.1M
Q3 25
$589.6M
Q2 25
$575.4M
Q1 25
$558.9M
Q4 24
$556.8M
Q3 24
$545.2M
Q2 24
$544.6M
Q1 24
$554.0M
Total Assets
SHLS
SHLS
TWST
TWST
Q4 25
$904.1M
$638.1M
Q3 25
$851.8M
Q2 25
$795.0M
Q1 25
$788.4M
Q4 24
$793.1M
Q3 24
$801.3M
Q2 24
$788.4M
Q1 24
$825.3M
Debt / Equity
SHLS
SHLS
TWST
TWST
Q4 25
Q3 25
Q2 25
Q1 25
0.25×
Q4 24
0.25×
Q3 24
0.26×
Q2 24
0.27×
Q1 24
0.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SHLS
SHLS
TWST
TWST
Operating Cash FlowLast quarter
$-4.1M
$-24.8M
Free Cash FlowOCF − Capex
$-11.3M
$-34.8M
FCF MarginFCF / Revenue
-7.6%
-33.5%
Capex IntensityCapex / Revenue
4.8%
9.6%
Cash ConversionOCF / Net Profit
-0.50×
TTM Free Cash FlowTrailing 4 quarters
$-16.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SHLS
SHLS
TWST
TWST
Q4 25
$-4.1M
$-24.8M
Q3 25
$19.4M
Q2 25
$-13.8M
Q1 25
$15.6M
Q4 24
$14.0M
Q3 24
$15.7M
Q2 24
$37.8M
Q1 24
$12.9M
Free Cash Flow
SHLS
SHLS
TWST
TWST
Q4 25
$-11.3M
$-34.8M
Q3 25
$9.0M
Q2 25
$-26.0M
Q1 25
$12.3M
Q4 24
$12.5M
Q3 24
$13.3M
Q2 24
$35.8M
Q1 24
$10.4M
FCF Margin
SHLS
SHLS
TWST
TWST
Q4 25
-7.6%
-33.5%
Q3 25
6.6%
Q2 25
-23.5%
Q1 25
15.4%
Q4 24
11.6%
Q3 24
13.0%
Q2 24
36.1%
Q1 24
11.4%
Capex Intensity
SHLS
SHLS
TWST
TWST
Q4 25
4.8%
9.6%
Q3 25
7.7%
Q2 25
11.0%
Q1 25
4.0%
Q4 24
1.4%
Q3 24
2.3%
Q2 24
2.0%
Q1 24
2.7%
Cash Conversion
SHLS
SHLS
TWST
TWST
Q4 25
-0.50×
Q3 25
1.63×
Q2 25
-1.00×
Q1 25
Q4 24
1.79×
Q3 24
Q2 24
3.21×
Q1 24
2.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SHLS
SHLS

System Solutions$122.0M82%
Components$26.3M18%

TWST
TWST

Industrial Chemicals$37.2M36%
Diagnostics$35.3M34%
Food Or Agriculture$12.8M12%
Academic Research$12.2M12%
Health Care$6.1M6%

Related Comparisons